Defensins are small antimicrobial peptides made by the human immune system, and despite decades of research, no defensin-based drug is approved yet. The most advanced candidate, brilacidin, is a non-peptide defensin mimic that has only finished phase 2 trials.[5][6] Today, defensins are used in clinics mainly as a diagnostic marker: FDA authorized an alpha-defensin test for joint replacement infections in 2019.[9]
This page is part of our peptide basics hub. For how defensins compare with other antimicrobial peptides, see LL-37 vs defensins vs magainin.
Bottom line
- Established: defensins are a key part of innate immunity in the gut, skin and white blood cells.[1]
- Established: an alpha-defensin joint fluid test helps diagnose prosthetic joint infection.[9][10]
- Preliminary: defensin drugs for infection and inflammatory bowel disease work in animals but lack human efficacy data.[3][8]
- Not yet: no defensin or defensin mimetic has passed a phase 3 trial.
What defensins are
Defensins are small peptides, a few dozen amino acids long, held in a compact shape by three disulfide bonds (bridges between cysteine building blocks). Humans make two main families:[1]
| Family | Main examples | Where they’re made | Roles |
|---|---|---|---|
| Alpha-defensins | HNP1-4 | Neutrophils (white blood cells) | Kill engulfed microbes |
| Alpha-defensins | HD5, HD6 | Paneth cells in the small intestine | Shape gut bacteria, guard the lining |
| Beta-defensins | hBD1-4 | Skin, airways, gut and other linings | Kill microbes, attract immune cells |
Beyond killing bacteria, fungi and some viruses, defensins attract immune cells and help regulate inflammation and the gut microbiome.[1] Our guide to peptides and the gut microbiome covers that last role in more depth.
Why defensins are hard to turn into drugs
Reviews highlight several obstacles:[1][2]
- Manufacturing: getting all three disulfide bonds to form in the right places is difficult and costly.
- Activity in the body: many defensins lose antimicrobial power in the salt and protein levels of blood and tissue.
- Toxicity and immune effects: because they also signal immune cells, high doses could stir up inflammation.
These hurdles explain why developers have turned to simpler mimics and to non-human defensins.
Candidates and key studies
| Candidate | What it is | Stage | Use studied |
|---|---|---|---|
| Brilacidin | Non-peptide small molecule that mimics defensins | Phase 2 completed | Skin infections, oral mucositis, COVID-19[5][6] |
| Plectasin (and variants) | Defensin from a fungus | Animal studies | Pneumococcal and staph infections[3][4] |
| Recombinant hBD2 | Human beta-defensin 2 | Animal studies | Inflammatory bowel disease[8] |
| Alpha-defensin test | Diagnostic, not a drug | FDA-authorized 2019 | Prosthetic joint infection[9] |
Brilacidin. Brilacidin is described as a non-peptide defensin-mimetic molecule: a small synthetic compound built to copy the shape and charge of defensins without being a peptide.[5] A double-blind phase 2 trial in 215 people with acute bacterial skin infections compared three brilacidin dosing schedules with daptomycin, a standard antibiotic.[6] The registry entry lists no posted results, and we could not find full peer-reviewed results. Other phase 2 trials have tested it as a mouth rinse for radiation-induced mouth sores and in hospitalized COVID-19 patients.
Plectasin. In 2005, researchers isolated plectasin, the first defensin found in a fungus. It could be made at high yield, was especially active against Streptococcus pneumoniae, including resistant strains, and cleared pneumococcal infections in mice as well as vancomycin and penicillin did, with very low toxicity in mice.[3] A 2010 study showed it works by binding Lipid II, a building block of the bacterial cell wall, rather than by punching holes in membranes.[4]
Human beta-defensin 2 for colitis. Recombinant hBD2 given by injection reduced gut inflammation in three mouse models of inflammatory bowel disease, with effects the authors described as on par with anti-TNF drugs and steroids. It appeared to work by calming dendritic cells (immune cells that direct inflammation) rather than by killing bacteria.[8]
Defensins as a diagnostic test
When a hip or knee replacement becomes infected, the immune system floods the joint fluid with neutrophils, which release alpha-defensins. In 2019, FDA granted a De Novo authorization, a pathway for new low-to-moderate-risk devices, to a lateral flow test that measures alpha-defensin in joint fluid.[9]
A 2021 meta-analysis of 17 studies with 1,443 cases found the lateral flow test had a pooled sensitivity of 83% and specificity of 95%. In practical terms, a positive result strongly suggests infection, while a negative result doesn’t fully rule it out.[10] Clinicians use it alongside other tests, not alone.
Defensins and Crohn’s disease
A 2005 study found that people with Crohn’s disease of the ileum (the last section of the small intestine) had less antibacterial activity in their gut lining and lower levels of the Paneth cell alpha-defensins HD5 and HD6. The drop did not depend on how inflamed the tissue was and was not seen in Crohn’s disease of the colon or in ulcerative colitis. In mice, changing HD5 levels shifted gut bacteria.[7] This makes defensins a research target in inflammatory bowel disease, but no defensin treatment has been tested for efficacy in human IBD trials.
Limitations
- Most drug data come from mice and lab dishes.
- Brilacidin, the only candidate with sizable human trials, is not a defensin itself, and full results are not published.
- Defensin levels change with infection, inflammation and diet, so linking them to a single disease is complex.[1]
What’s next
On ClinicalTrials.gov in October 2026, we found no recruiting trial of a defensin drug. Diagnostic work continues: a study at the Hospital for Special Surgery in New York is enrolling children to test whether alpha-defensin and other joint fluid proteins can better detect septic arthritis.[11] For the wider antibiotic picture, see our guide to antimicrobial peptides research. The human cathelicidin LL-37 and the immune peptide thymosin alpha-1 are covered on their profile pages, and our natural vs synthetic peptides guide explains how natural peptides are redesigned as drugs.
Questions to discuss with a clinician
- If I have a painful joint replacement, is an alpha-defensin test part of my workup?
- How would a positive or negative result change my treatment?
- Is my gut condition linked to changes in natural antimicrobial peptides?
- Are there trials of new anti-infective drugs I could join?
